Treatment of recurrent acute myelogenous leukaemia at a single centre over a 10-year period.
Davis
C L
CL
Department of Medical Oncology, St. Bartholomew's Hospital, London, UK.
Rohatiner
A Z
AZ
Amess
J
J
Lim
J
J
Lister
T A
TA
D000293:Adolescent; D000328:Adult; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D013866:Thioguanine / Q000008:administration & dosage; D006113:United Kingdom / Q000453:epidemiology
D007370:Interferon Type I; D000677:Amsacrine; D003561:Cytarabine; D004317:Doxorubicin; D008942:Mitoxantrone; D013866:Thioguanine